Assessment of Factors Affecting Symptom Control in Asthmatic Patients

Waqas Rasheed Rashid Naseem Khan

Department of Medicine & Allied Liaquat College of Medicine and Dentistry Darul Sehat Hospital Karachi Pakistan.

Correspondence to: Dr. Waqas Rasheed Email: dr.waqasrasheed@gmail.com ORCiD: 0000-0001-7820-8184

Running title: Factors Affecting Symptom Control in Asthmatic Patients

ABSTRACT

Objective: To assess the level of symptoms control achieved by Asthmatic Patients in Pakistan and the associated factors making an impact on symptom control.

Methods: A prospective cross-sectional study was carried out at Darul Sehat Hospital from December 2018 till December 2019. All patients of irrespective of age and gender diagnosed as bronchial asthma were consecutively included. Symptom control was assessed according to Global Initiative for Asthma (GINA) assessment tool. Prevalence of asthma symptom control was determined while association of risk factors with uncontrolled asthma was also evaluated.

Results: Of 113 patients the mean age was 36.8 +-16.6 years. There were 76 (67.3%) patients had uncontrolled asthma. A significant association of uncontrolled asthma was observed with incorrect inhaler technique (p value of 0.039) more than 10 years asthma duration (p value <0.001) lack of inhaled corticosteroid (ICS) use (p value 0.004) Gastroesophageal Reflux Disease (GERD) (p value <0.001) more than 1 episode of asthma exacerbation in last 12 months (p value <0.001) and with high use of short acting beta agonists (p value <0.001).

Conclusion: A higher prevalence of uncontrolled asthma was observed in our cohort with significant association of uncontrolled asthma with poor inhaler technique lack of ICS use GERD more than 10 years asthma duration and more than 1 asthma exacerbation episode in last 12 months.

Keyword: Asthma bronchial spasm bronchoconstriction bronchodilator agents bronchial diseases.

 

INTRODUCTION

Asthma is a common disease of airways characterized by chronic inflammation and usually presents with symptoms like shortness of breath cough chest tightness and wheezing and these symptoms do vary over time in intensity.1 Asthma has a great global impact. Estimated prevalence of Asthma in Pakistan as highlighted by report on Global burden of Asthma is 4.3%.2 There are multiple factors that trigger asthma symptoms which include allergen exposure smoking allergic rhinitis sinusitis gastroesophageal reflux disease (GERD) inadequate use of inhaled corticosteroids (ICS) that include poor adherence to medication and inappropriate inhaler technique.3 4 Asthma has a great impact on population and when poorly controlled leads to considerable economic impact with loss of work days school attendance frequent hospital admissions poor quality of life and ultimately death.5 According to a study approximately 24.2% of the patients with asthma have well controlled asthma.6 There are multiple studies from different parts of the world that reflect asthma control and also the influence of these factors over symptom control but no such study has been conducted in Pakistan.7-10 According to a study 45% patients had uncontrolled asthma.7 Therefore the objective behind conducting this study was to assess the level of symptoms control achieved by asthmatic patients in developing country like Pakistan and to assess the factors which are making an impact on symptom control so that these factors can be focused and managed effectively in order to achieve good control over symptoms and lead a healthy life.

 

METHODS

A prospective cross sectional study was undertaken at Darul Sehat Hospital for duration of 1st December 2018 till 30th November 2019 after Institutional Review Board (IRB) approval. Taking frequency of asthma control as 24.2%6 confidence interval (CI) as 95% and precision as 8% the estimated sample size came out to be 111 but total 113 patients were included. Non Probability Consecutive sampling technique was used for sample collection. Both male and female patients of either age presenting with respiratory symptoms such as cough shortness of breath chest tightness and wheezing and were diagnosed as having bronchial asthma by physician on the basis of appropriate clinical history and examination or proved by spirometry were included. Patients were excluded if they refused to give consent had clinical features that suggested other diagnoses on treatment of pulmonary tuberculosis or previously treated for pulmonary tuberculosis or had severe exacerbation requiring hospitalization. Written informed consent was obtained from all patients after explaining pros and cons of the study. Patients fulfilling inclusion criteria were interviewed. Demographic data including age gender height weight comorbid conditions such as diabetes mellitus hypertension ischemic heart disease smoking status time since asthma diagnosis family history of asthma history of atopy (self-reported history of allergic rhinitis or eczema and occupation were noted.

Symptom control was assessed according to Global Initiative for Asthma (GINA) symptom control assessment tool.11 (Table 1) This tool comprise frequency of symptoms reported in daytime night awakening due to asthma any activity limitation as a result of asthma and number of times reliever medication taken per week over the period of 4 weeks. Symptom control was labeled as well controlled if all of these features were absent. In the presence of 1 or 2 features symptom control was labeled as partially controlled. If 3 or more of these features were present then symptom control was labeled as uncontrolled. Record of current medications in patient s use was obtained by either seeing prescription of patients own chest physician or patient showing medicines at the time of interview.

Presence of different risk factors was also noted. GERD was recorded as self-reported sensation of retrosternal burning requiring medication. Allergic rhinitis was recorded as self-reported recurrent episodes of nasal discharge and sneezing related to allergen exposure or seasonal change. Asthma exacerbations were defined as worsening of symptoms requiring addition of a course of oral corticosteroids according to the recommendation of patient s own chest physician.11 The number of asthma exacerbations experienced over past 12 months was retrospectively assessed by asking the patients the number of times patient needed to modify usual treatment or had to take courses of oral corticosteroids. Eosinophil counts were recorded from patients complete blood count (CBC). Exposure to the occupational agents leading to development of symptoms and the use of drugs that may precipitate symptoms such as salicylates nonsteroidal anti-inflammatory drugs (NSAIDs) or beta-blockers were also noted as potential asthma triggering factors. Patient s current medications were also noted. High use of reliever medicine was assessed by asking the patient about consumption of short acting beta agonist (SABA) inhaler within 1 month. Inadequate use of inhaled corticosteroids was assessed by presence of either of the following: Not ever prescribed or poor compliance or incorrect inhaler technique. Inhaler technique for the use of a metered-dose or dry powder inhaler was evaluated by the investigator by asking the patients to demonstrate their usual inhaler technique and recorded as incorrect or correct according to previously reported evaluation of inhaler use.12 Respiratory infections were defined as self-reported episodes of increasing cough and purulent sputum for which a course of antibiotic medications were prescribed to the patient by the primary chest physician.

Data entry and analysis was done using statistical package for social sciences (SPSS) version 22.0. All qualitative variables were expressed in terms of frequency and percentages While all quantitative variables were expressed in terms of mean and standard deviation (SD). Prevalence of different levels of symptom control in asthma patients was also calculated. Effects modifiers were controlled by stratification to see their effect on poor symptom control in asthma patients. Chi-square test/Fisher-exact was applied and p value of ≤0.05 was taken as significant.

 

RESULTS

Total 113 patients were included in this study. Mean age of the patients was 36.8 +- 16.6 years. Mean duration of asthma was 18.0 +- 12.0 years. Family history of asthma was positive in 82 (72.6%). Among co-morbid conditions hypertension was common and was present in 23 (20.4%) of the patients. Among presenting symptoms shortness of breath was the most common symptom and was present in 111 (98.2%) patients. Chest tightness was present in all patients. Among patients with atopy allergic rhinitis was present in 108 (95.6%) patients. Total 68 (60.2%) had greater than 1 episode of asthma exacerbation in last 12 months. Total 35 (31.0%) were smokers and 78 (69.0%) were nonsmokers. All the patients used inhalers and among them 108 (95.6%) had the incorrect technique of using inhaler. Total 85 (75.2%) had gastroesophageal reflux disease (GERD). Moreover uncontrolled asthma was present in 76 (67.3%) of the cases.

Among patients taking medications for asthma short acting beta agonist (SABA) was used by 97 (85.8%) patients inhaled corticosteroid (ICS) was used by 46 (40.7%) patients long acting beta agonist (LABA) was used by 46 (40.7%) patients and leukotriene receptor agonist (LTRA) was used by 70 (61.9%) patients. Table 2 describes briefly the medications used.

Uncontrolled asthma was significantly higher in patients without any history of diabetes mellitus (p value of 0.002) in patients using inhalers incorrectly (p value of 0.039) in patients with more than 10 years asthma duration (p value <0.001) in patients with GERD (p value <0.001) and in patients having >1 episode of asthma exacerbation in last 12 months (p value <0.001) (Table 3). Uncontrolled asthma was significantly higher in patients not taking ICS (p value of 0.004) and in patients with high use of SABA (p value <0.001) (Table 4).

 

DISCUSSION

Asthma is a major prevalent disease globally accounting for its presence in approximately 300 million people and is responsible for almost 250 000 deaths prematurely annually.13 Asthma has a negative impact on the patients as well as their communities by causing loss of work and school hours impaired quality of life frequent hospitalizations frequent visit to the emergency department (ED) and in severe cases death may also occur. A significant portion of costs related to asthma has been attributed to severe as well as uncontrolled asthma. In the present study we determined a developing country s perspective from Asia for evaluating symptom control in asthmatic patients. Moreover factors related to poor symptom control in asthma were also assessed.

The results of our study demonstrated a high prevalence of uncontrolled asthma in our population. A high prevalence of uncontrolled asthma has been reported by other studies but the reported prevalence was lower as compared to our study.6 This could be due to larger sample size of the previous studies. Another study with physician diagnosed asthma demonstrated a high prevalence of uncontrolled asthma.14 In our study GINA assessment tool was labeled to evaluate asthma symptom control which yielded high prevalence of uncontrolled asthma whereas an international study reported a lower prevalence of uncontrolled asthma.15

Our study has shown that well controlled asthma has a lower prevalence in our population. This contrasts with the results reported by other authors.6 Such a difference in results could be due to the reason that these previous studies were conducted on a larger sample size. Moreover the difference in genetic and ethnic factors between the study populations could be another postulated reason for difference in asthma symptom control.

A high prevalence of uncontrolled asthma was reported in women in our study. Studies have also reported a higher prevalence of uncontrolled asthma in females.16 17 In childhood asthma has a higher prevalence in boys but at puberty there is an increase in sex hormones that causes in increase in asthma in females.18 Moreover females have high IgE levels at puberty and this may result in triggering of symptoms by dust or pollen exposure with associated reduced ratio of FEV1/FVC.19

In our study uncontrolled asthma was higher in patients having family history of asthma. An important risk factor of asthma is having its family history and evaluation of familial risk can help identify the patients who have a high risk of asthma. However a study has shown that patients having family history of asthma have best controlled asthma.20 The pathogenesis of asthma involves a complex interaction of various ethnic genetic and life style factors and this could be the reason behind a varying prevalence of asthma control between these studies.

Our study results reported that patients with uncontrolled asthma had lower incidence of diabetes. Another study has reported that diabetes has not a significantly high prevalence in patients with difficult to treat asthma.21 Insulin resistance metabolic syndrome and diabetes have an important pathophysiological role in development of asthma.22

The results of our study have shown that history of atopy was higher in patients with uncontrolled asthma as compared with partially controlled/well controlled asthma. Similar results have been shown by a previous study.23 According to a study atopic patients usually have onset of asthma at an earlier age; however the study concluded that aeroallergens were not the predictors of asthma control.24 Among atopy nasal diseases such as allergic rhinitis or rhinosinusitis are among prevalent chronic respiratory illnesses.

Our study has shown that uncontrolled asthma was significantly higher in patients with incorrect inhaler technique. A regional study has reported a similar observation that poorly controlled asthma patients and those patients whose FEV1 is less than 70% have error in their technique of using inhalers.25 Another study reported a high prevalence of incorrect inhaler technique which reduced at the follow up visit indicating the importance of proper educating regarding the inhaler technique.26

According to our study results patients with uncontrolled asthma had significantly higher gastroesophageal reflux disease (GERD). A previous study has shown that in patients with uncontrolled asthma GERD prevalence was higher.27 Another study has demonstrated that GERD was the third most common comorbid condition in patients with asthma after rhinitis or sinusitis and cardiovascular diseases.28

A significantly higher number of patients in our study with uncontrolled asthma had duration of asthma of more than 10 years. Another study also reported a statistically significant difference between duration of asthma and asthma control with uncontrolled asthma population having a longer asthma duration.29 Longer asthma duration has been linked to poor asthma control due to irreversible obstruction to airflow. IgE cytokines derived from T cells and mast cells start the early asthma reaction whereas activation of eosinophils have their role in persistent asthma symptoms characterizing chronic obstruction to airflow which later becomes irreversible after a longer duration.

Our study results also demonstrated that asthma exacerbations were significantly higher in patients having uncontrolled asthma. Another study also reported that exacerbation in last 12 months is a significant risk factor for poor asthma control.6 Asthma exacerbations have a negative impact on quality of life and are a source of burden on healthcare. Therefore intense management should be addressed for its management and prevention of future exacerbations.

Our study has shown that proportion of patients not using inhaled corticosteroids (ICS) was significantly high in cases of uncontrolled asthma. Another study has reported that patients reported good asthma control with the consistent use of ICS.14 ICS has a good role in management of asthma by reducing its symptoms and improving quality of life by reducing the number of exacerbations asthma related hospitalizations and improving pulmonary function. In addition our study has further shown that excessive use of SABA was significantly higher in patients with uncontrolled asthma a finding also reported by other studies.6 15 Use of short acting beta agonist as a rescue is a marker for severity of asthma and its high rate in uncontrolled asthma could suggest that the patients might not be using the maintenance medications or the dosage of the maintenance medications might not be enough.

Our study is not without certain limitations. First of all this study was undertaken on a small sample size. Another limitation of this study was that some patients reported use of herbal medications for asthma control and the content of such medicines is obscured. It may contain bronchodilator or steroids which remain unrevealed so this may have certain impact on symptom control which couldn t be highlighted in the present study. Another limitation is that spirometry wasn t done in every patient labeled as having asthma some patients were physician diagnosed so this may raise query on asthma diagnosis of such patients. Moreover many patients reported to have asthma may have persistent airflow limitation or asthma chronic obstructive pulmonary disease (COPD) overlap (ACO) which requires spirometry for differentiation.

These limitations aside we believe to the best of our knowledge that this study was the initial step in determining the level of asthma control in a developing country like Pakistan. Moreover factors associated with poor asthma control were also evaluated. It is recommended that further studies on larger sample size should be carried out. Moreover it is further recommended that studies should also be carried out on pediatric asthma patients and their risk factors so that an insight could also be established regarding asthma control in pediatric population.

 

CONCLUSION

A high proportion of patients had uncontrolled asthma in our population. Level of uncontrolled asthma was significantly higher in patients with incorrect inhaler usage technique GERD duration of symptoms more than 10 years more than 1 episode of asthma exacerbation in past 12 months absent use of ICS and high use of SABA.

ETHICAL APPROVAL: The study was approved by the Ethical Review Committee Liaquat College of Medicine and Dentistry Darul Sehat Hospital Karachi Pakistan.

AUTHORS CONTRIBUTION

WR: Study design & concept designed the Questionnaire collected the data and performed data analysis. RNK: Study design & concept drafting the manuscript approved the final manuscript.

 

CONFLICT OF INTEREST: The authors have declared that no conflict of interest.

FUNDING: None.

Received: October 18 2020

Accepted: December 15 2020

 

Table 1: Asthma control according to Global Initiative for Asthma (GINA) for adults

Asthma symptom control

Symptoms in the past
4 weeks

Well Controlled

Partly
Controlled

Uncontrolled

Daytime symptoms more than 2x/week

No criterion
applies

1-2 criteria
apply

3-4 criteria
apply

Nocturnal awakening
due to asthma at any time

Reliever >2x/week

Any limitation of daily
activity due to asthma


 

Table 2: Medication use in study population

 

n

%

Short acting beta agonist (SABA)

97

85.8

High use of SABA

34

30.1

Inhaled corticosteroid

32

28.3

Long acting beta agonist

46

40.7

Leukotriene receptor agonist

70

61.9

Methylxanthine

3

2.7

Long acting muscarinic antagonist

2

1.8

Nonsteroidal anti-inflammatory drugs

3

2.7

Beta blocker

12

10.6

Salicylates

1

0.9

SABA: Short Acting Beta Agonist


 

Table 3: Baseline factors significantly associated with asthma control

Factors

Total

Asthma Symptom Control

p-value

Uncontrolled

(n=76)

Well/Partially controlled

(n=37)

Diabetes Mellitus

 

 

 

Present

15 (13.3)

15 (100)

0 (0)

0.002**

Absent

98 (86.7)

61 (62.2)

37 (37.8)

Hypertension

Present

23 (20.4)

21 (29.3)

2 (8.7)

0.006*

Absent

90 (79.6)

55 (61.1)

35 (38.9)

Inhaler technique

 

 

 

Correct

5 (4.4)

1 (20)

4 (80)

0.039**

Incorrect

108 (95.6)

75 (69.4)

33 (30.6)

GERD

 

 

 

Present

85 (75.2)

65 (76.5)

20 (23.5)

<0.001*

Absent

28 (24.8)

11 (39.3)

17 (60.7)

Duration of symptoms

≤10 years

31 (27.4)

7 (22.6)

24 (77.4)

<0.001*

>10 years

82 (72.6)

69 (84.1)

13 (15.9)

Number of exacerbations

≤1

45 (39.8)

19 (25)

26 (70.3)

<0.001*

>1

68 (60.2)

57 (75)

11 (29.7)

Cough

 

 

Absent

22 (19.5)

9 (11.8)

13 (35.1)

0.003*

Present

91 (80.5)

67 (88.2)

24 (64.9)

Shortness of breath

 

 

 

 

Absent

2 (1.8%)

0 (0)

2 (5.4)

0.105

Present

111 (98.2)

76 (100)

35 (94.6)

Wheezing

 

 

 

 

Present

105 (92.9)

73 (96.1)

32 (86.5)

0.111**

Absent

8 (7.1)

3 (3.9)

5 (13.5)

-GERD: Gastroesophageal Reflux Disease

- Following factors were found insignificantly associated with asthma control: Gender (p-value 0.289*) Family history of asthma (p-value 0.703*) Ischemic heart disease (p-value 0.155*) Atopy (p-value 0.155*) Eosinophil count (p-value 0.312*)

- *Chi-square test applied **Fishers exact test applied

 

Table 4: Comparison of asthma control with medication use

 

Total

Asthma Symptom Control

p-value

Uncontrolled

Well/Partially controlled

SABA

 

 

 

Present

97 (85.8)

67 (88.2)

30 (81.1)

0.390*

Absent

16 (14.2)

9 (11.8)

7 (18.9)

ICS

 

 

 

Present

32 (28.3)

15 (19.7)

17 (45.9)

0.004*

Absent

81 (71.7)

61 (80.3)

20 (54.1)

LABA

 

 

 

Present

46 (40.7)

35 (46.1)

11 (29.7)

0.097*

Absent

67 (59.3)

41 (53.9)

26 (70.3)

LTRA

 

 

 

Present

70 (61.9)

45 (59.2)

25 (67.6)

>0.999**

Absent

43 (38.1)

31 (40.8)

12 (32.4)

LAMA

 

 

 

Present

2 (1.8)

2 (2.6%)

0 (0)

>0.999**

Absent

111 (98.2)

74 (97.4)

37 (100)

Methylxanthine

 

 

 

Present

3 (2.7)

2 (2.6)

1 (2.7)

>0.999**

Absent

110 (97.3)

74 (97.4)

36 (97.3)

NSAIDs

 

 

 

Present

3 (2.7)

3 (3.9%)

0 (0)

0.550**

Absent

110 (97.3)

73 (96.1)

37 (100)

Beta blocker

 

 

 

Present

12 (10.6)

11 (14.5%)

1 (2.7)

>0.999**

Absent

101 (89.4)

65 (85.5)

36 (97.3)

High use of SABA

 

 

 

Present

34 (30.1)

34 (44.7)

0 (0)

<0.001*

Absent

79 (69.9)

42 (55.3)

37 (100)

- ICS: Inhaled Corticosteroid LABA: Long Acting Beta Agonist LAMA: Long Acting Muscarinic Antagonist LTRA: Leukotriene Receptor Agonist. NSAISs: Nonsteroidal Anti-Inflammatory Drugs SABA: Short Acting Beta Agonist

-*Chi-square test applied * Fisher s exact test applied

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

REFERENCES

1.        Becker AB Abrams EM. Asthma guidelines: the Global Initiative for Asthma in relation to national guidelines. Curr Opin Allergy Clin Immunol 2017; 17:99-103. doi: 10.1097/ACI.0000000000000346.

2.       Masoli M Fabian D Holt S Beasley R; Global Initiative for Asthma (GINA) Program. The global burden of asthma: executive summary of the GINA Dissemination Committee report. Allergy 2004; 59:469-78. doi: 10.1111/j.1398-9995.2004.00526.x.

3.       Kang HR Song HJ Nam JH Hong SH Yang SY Ju S et al. Risk factors of asthma exacerbation based on asthma severity: a nationwide population-based observational study in South Korea. BMJ Open 2018 22; 8:e020825. doi: 10.1136/bmjopen-2017-020825. 

4.      Lin J Wang W Chen P Zhou X Wan H Yin K et al. Prevalence and risk factors of asthma in mainland China: The CARE study. Respir Med 2018; 137:48-54. doi: 10.1016/j.rmed.2018.02.010.

5.       Stewart WF Ricci JA Chee E Morganstein D. Lost productive work time costs from health conditions in the United States: results from the American Productivity Audit. J Occup Environ Med 2003; 45:1234-46. doi: 10.1097/01.jom.0000099999.27348.78.

6.      Gebremariam TH Binegdie AB Mitiku AS Ashagrie AW Gebrehiwot KG Huluka DK et al Level of asthma control and risk factors for poor asthma control among clinic patients seen at a Referral Hospital in Addis Ababa Ethiopia. BMC Res Notes 2017; 10:558. doi: 10.1186/s13104-017-2887-z. 

7.       Price D Fletcher M van der Molen T. Asthma control and management in 8 000 European patients: the REcognise Asthma and LInk to Symptoms and Experience (REALISE) survey. NPJ Prim Care Respir Med 2014; 24:14009. doi: 10.1038/npjpcrm.2014.9.

8.      Demoly P Annunziata K Gubba E Adamek L. Repeated cross-sectional survey of patient-reported asthma control in Europe in the past 5 years. Eur Respir Rev 2012; 21:66-74. doi: 10.1183/09059180.00008111.

9.      Mintz M Gilsenan AW Bui CL Ziemiecki R Stanford RH Lincourt W et al. Assessment of asthma control in primary care. Curr Med Res Opin 2009; 25:2523-31. doi: 10.1185/03007990903218655. 

10.    Braido F Brusselle G Guastalla D Ingrassia E Nicolini G Price D et al. LIAISON Study Group. Determinants and impact of suboptimal asthma control in Europe: the international cross-sectional and longitudinal assessment on asthma control (LIAISON) study. Respir Res 2016; 17:51. doi: 10.1186/s12931-016-0374-z. 

11.     Horak F Doberer D Eber E Horak E Pohl W Riedler J et al. Diagnosis and management of asthma - Statement on the 2015 GINA Guidelines. Wien Klin Wochenschr 2016; 128(15-16):541-54. doi: 10.1007/s00508-016-1019-4.

12.    Paasche-Orlow MK Riekert KA Bilderback A Chanmugam A Hill P Rand CS et al. Tailored education may reduce health literacy disparities in asthma self-management. Am J Respir Crit Care Med 2005; 172:980-6. doi: 10.1164/rccm.200409-1291OC. 

13.    Bousquet J Kiley J Bateman ED Viegi G Cruz AA Khaltaev N et al. Prioritised research agenda for prevention and control of chronic respiratory diseases. Eur Respir J 2010 ; 36:995-1001. doi: 10.1183/09031936.00012610.

14.    Gebremariam TH Sherman CB Schluger NW. Gebremariam TH Sherman CB Schluger NW. Perception of asthma control among asthmatics seen inChest Clinic at Tertiary Hospital Addis Ababa Ethiopia. BMC Pulm Med 2019; 19:187. doi: 10.1186/s12890-019-0959-7.

15.    Marchioro J Gazzotti MR Nascimento OA Montealegre F Fish J Jardim JR. Level of asthma control and its relationship with medication use in asthma patients in Brazil. J Bras Pneumol 2014; 40:487-94. doi: 10.1590/s1806-37132014000500004.

16.    Torchyan AA. Asthma control in Saudi Arabia: Gender implications. Allergy Asthma Proc 2017; 38:47-53. doi: 10.2500/aap.2017.38.4035.

17.    Abrahamsen R Gundersen GF Svendsen MV Klepaker G Kongerud J Fell AKM. Possible risk factors for poor asthma control assessed in a cross-sectional population-based study from Telemark Norway. PLoS One 2020; 15:e0232621. doi: 10.1371/journal.pone.0232621. 

18.    Zein JG Erzurum SC. Asthma is Different in Women. Curr Allergy Asthma Rep 2015 ; 15:28. doi: 10.1007/s11882-015-0528-y.

19.    Haselkorn T Szefler SJ Simons FE Zeiger RS Mink DR Chipps BE et al. TENOR Study Group. Allergy total serum immunoglobulin E and airflow in children and adolescents in TENOR. Pediatr Allergy Immunol 2010; 21:1157-65. doi: 10.1111/j.1399-3038.2010.01065.x.

20.   Bednarek A Bodajko-Grochowska A Bartkowiak-Emeryk M Klepacz R Ciolkowski J Zarzycka D et al. Demographic and medical factors affecting short-term changes in subjective evaluation of asthma control in adolescents. Postepy Dermatol Alergol 2018 ; 35:259-66. doi: 10.5114/ada.2018.76221. 

21.    Hekking PP Amelink M Wener RR Bouvy ML Bel EH. Comorbidities in Difficult-to-Control Asthma. J Allergy Clin Immunol Pract 2018; 6:108-13 doi: 10.1016/j.jaip.2017.06.008. 

22.   Baffi CW Wood L Winnica D Strollo PJ Jr Gladwin MT Que LG et al. Metabolic syndrome and the lung. Chest 2016; 149:1525-34. doi: 10.1016/j.chest.2015.12.034.

23.   Lin J Gao J Lai K Zhou X He B Zhou J et al. The characteristic of asthma control among nasal diseases population: Results from a cross-sectional study. PLoS One 2018 ; 13:e0191543. doi: 10.1371/journal.pone.0191543. 

24.   Agondi RC Andrade MC Takejima P Aun MV Kalil J Giavina-Bianchi P. Atopy is associated with age at asthma onset in elderly patients. J Allergy Clin Immunol Pract 2018; 6):865-71. doi: 10.1016/j.jaip.2017.10.028.

25.   Chogtu B Holla S Magazine R Kamath A. Evaluation of relationship of inhaler technique with asthma control and quality of life. Indian J Pharmacol 2017; 49:110-5. doi: 10.4103/0253-7613.201012.

26.   Harnett CM Hunt EB Bowen BR O Connell OJ Edgeworth DM Mitchell P et al. A study to assess inhaler technique and its potential impact on asthma control in patients attending an asthma clinic. J Asthma 2014; 51:440-5. doi: 10.3109/02770903.2013.876650.

27.   Jaimchariyatam N Wongtim S Udompanich V Sittipunt C Kawkitinarong K Chaiyakul S et al. Prevalence of gastroesophageal reflux in Thai asthmatic patients. J Med Assoc Thai 2011; 94:671-8.

28.   Tomisa G Horvath A Szalai Z Muller V Tamasi L. Prevalence and impact of risk factors for poor asthma outcomes in a large specialist-managed patient cohort: a real-life study. J Asthma Allergy 2019; 12:297-307. doi: 10.2147/JAA.S211246.

29.   Albataineh E Al-Zayadneh E Al-Shagahin H Soloman AA Altarawneh A Aldmour I. Asthma Control and Its Predictive Factors in Adult Asthma Patients. J Clin Med Res. 2019; 11:807-17. doi: 10.14740/jocmr4021.